The effect of histamine and cimetidine on the growth of four human colon cancer cell lines was studied. Histamine significantly stimulated the uptake of tritiated thymidine in vitro in a dose dependent manner, to a maximum of 120% and 116% of controls for C170 and LIM2412, respectively. This effect was antagonised by cimetidine, but not diphenhydramine. 
animalsl4 and to induce tumour regression in man. 5 One controlled trial in gastric cancer has shown a significant survival advantage in patients who received postoperative cimetidine.6 These effects were largely attributed to the important effects of cimetidine on the immune function.
Our recent finding that cimetidine inhibited the growth of carcinogen induced colonic tumours in rats, with corresponding reductions in the cellular proliferative indices,7 led us to investigate further the role of histamine in colonic cancer. The present study examines the effect of histamine and cimetidine on colorectal cancer cell lines to determine the presence of a direct non-immunological effect in this type of malignancy.
Methods

MATERIALS
Four human colonic adenocarcinoma cancer cell lines were studied. C 1708 and LoVo9 were gifted by CRC Laboratories, Nottingham, UK and LIM2412 and LIM240510 were gifts from the Ludwig Institute, Melbourne, Australia. All cell lines were maintained in RPMI plus 10% fetal calf serum (FCS) (Cytosystems Pty Ltd, Australia) at 37°C in 5% CO2. Chemicals used were: cimetidine (Smithkline Beecham, Australia); diphenhydramine (Aldrich Pty Ltd, USA); isobutylmethylxanthine (IBMX), thymidine, and histamine hydrochloride (Sigma Chemical Co, St Louis, USA); 3H-methylthymidine (Dupont, USA) and; Hams Fl 2/MEM media (Cytosystems Pty Ltd, Australia).
CELL PROLIFERATION ASSAY
Tumour cells were suspended at a concentration of 1 x 105 cells/ml in RPMI-1 640 with 10% FCS, distributed onto a 96 well microtitre plate and incubated at 37°C for 24 hours. The cells were then synchronised by a further 24 hours' incubation in a 0X6 mmol/l solution of thymidine in serum free RPMI. The supematant was then replaced with Hams F12/MEM media containing the test drugs (histamine, diphenhydramine, and cimetidine) at a range of concentrations (1 X In the first experiment, 1 mm3 fragments of tumours developed from each cell line were subcutaneously implanted into anaesthetised animals (Hypnorm, Janssen Pharmaceutica, Australia). The mice were then randomly allocated to either treatment or control groups of 10 animals for each cell line. Control animals had free access to autoclaved deionised drinking water. For the animals in the treatment group, the water contained the histamine type 2 receptor antagonist, cimetidine, at a concentration of 0-4 mg/ml. As nude mice have previously been shown to drink an average of 5 (0-6) ml/day2 (as confirmed in our own laboratory), this would produce an oral intake of cimetidine that approximate to 100 mg/kg/day.2 Treatment began on the day of tumour implantation. The experiment ended when the tumours began to ulcerate, usually between the 21st and 28th days. The drinking water was renewed every three days until the end of the experiment. 2 After implantation, most xenografts grew into single spherical or ovoid tumours. The two greatest tumour perpendicular diameters were measured three times weekly with vernier callipers, and their volumes (V) were calculated by the formula V=0 5 lengthX (width). 2 13 In a few cases the tumours became bosselated, with two or more foci of tumour growth. In these cases each ovoid component of the tumour was measured separately, using the method described above, and the total volume was calculated from their sum. Those animals which failed to develop a tumour mass were excluded from analysis.
At the end of the experiment, all mice were killed by intraperitoneal dose of pentabarbitone sodium (Lethobarb, Virbas Pty Ltd, Australia). Tumours were harvested and fixed in 10% formalin for histological examination.
In the second experiment, xenografts were produced by a subcutaneous injection in the left flank of each animal of 1 X 106 C170 cells suspended in 100 jil of RPMI-1640. Immediately after this injection, the animals were randomised to treatment A suspension of 1 X 106 C 170 cells in 100 ,ul of RPMI-1640 was then injected subcutaneously in the region of the pump's orifice. In one group of 10 animals, the pump contained 0 -9% phosphate buffered saline (PBS) and the mice received no cimetidine. In the remaining three groups of 10 animals, the pump contained histamine at a concentration of 1 X 10-2 M in
Results
CELL PROLIFERATION ASSAY
Histamine produced a dose dependent stimulation of cell proliferation in the cell lines C170 (Fig 1A) and LIM2412 (Fig 1B) . A bell shaped curve of response to histamine was seen, with maximal stimulation occurring at histamine concentrations of 1 X 10-8 M and IX10-7 M for C170 and LIM2412 respectively. For Neither histamine nor cimetidine had any significant effect on the cell lines LIM2405 or LoVo (data not shown).
QUANTIFICATION OF STIMULATED INTRACELLULAR CAMP
Histamine stimulated a dose dependent increase in intracellular cAMP production in C170 cells to a maximum of 275% of basal levels (Fig 2) . This effect was antagonised by cimetidine but not by diphenhydramine. significantly differ between control animals and those receiving either cimetidine or histamine and neither did the proportion of animals in which tumours were successfully induced.
In the first experiment, the growth of both C 170 and LIM2412 tumours was significantly inhibited by cimetidine at a dose of 100 mg/kg/day, with reductions in the final mean tumour volumes to 43 5% and 59 5% of controls, respectively (Fig 3) . The remaining two cell lines, LIM2405 and LoVo, were not significantly effected (data not shown).
The effect of cimetidine on C170 tumour growth was dose dependent, plateauing at a dose of 50 mg/kg/day (Fig 4) .
Diphenhydramine, at doses of 5 mg/kg/day and 20 mg/kg/day, did not significantly effect tumour growth (data not shown).
Exogenous histamine produced an increase in the final mean tumour volume to 163/6% of control ( Fig 5) . of xenografts of two colon cancer cell lines, has also been described previously.14 In addition, cimetidine has been found to have an inhibitory effect on several other tumour typesl-4 and has induced a clinical response in human cancers. 5 6 It has been thought that cimetidine acts through immunostimulation1-4 15-17 mediated via histamine receptors on lymphocyte suppressor cells;18 19 however, the results of our experiments in vitro suggest that a direct inhibitory effect on tumour cell proliferation is also present, for at least some tumours.
The fact that histamine stimulation of in vitro growth for both C1 70 and LIM2412 is antagonised by cimetidine, but not diphenhydramine, suggests that this is an H2 receptor phenomenon. This is confirmed by histamine's stimulation of intracellular cAMP production in C 170 cells, again antagonised by cimetidine, as these receptors are known to be linked to adenylate cyclase.20 Functional H2 receptors have been reported on other tumour types, including gastric cancer21 and melanoma.22
A recent paper by Watson et al 23 found that, in contrast to our own results, histamine did not stimulate the in vitro proliferation of C 170, but did stimulate the growth of the gastric cancer cell line, MKN45, both in vivo and in vitro. Histamine was found to stimulate intracellular cAMP production in MKN45, but not C170, suggesting the presence of tumour H2 receptors on the former cell line as the mechanism for histamine's action. The effect of histamine on the rate of cellular proliferation of C170 in our model was modest, as was the volume of production of cAMP. The difference in findings between our groups may represent differences in cell characteristics that have arisen after a period of separate evolution in different laboratories, as well as differences in assay technique. It would be interesting to see the effect of cimetidine treatment of xenografts on Watson' These experiments have shown that histamine has a trophic effect on at least two colorectal cell lines which can be antagonised by the H2 antagonist, cimetidine. The response of these cell lines to histamine in vitro points to the importance of functional, tumour borne H2 receptors. 
